Assessment reveals no significant difference in gamma band power between Alzheimer's and healthy subjects, indicating challenges in treatment effectiveness.
Gamma transcranial alternating current stimulation (Gamma-tACS) is used for treating Alzheimer's disease (AD). The changes in the Gamma band power (GBP) of Electroencephalogram (EEG) manifested by AD can justify the reliability of enhancing the GBP via the Gamma-tACS. The EEG is the electric potential originating from the neural activity of the human brain. Our objective is to statistically investigate how far the AD patients differ from the healthy subjects in terms of GBP of resting-state EEG at the frontal electrodes. The dataset contains EEG recordings from 65 participants comprising 36 AD patients with an age of 66.39 ± 7.89 and 29 healthy subjects with an age of 67.90 ± 5.40. As a major finding, the Wilcoxon rank-sum test reveals that the difference in GBP of AD patients and healthy subjects is not significant at frontal polar 1 (FP1) (p = 0.81), FP2 (p = 0.48), frontal 3 (F3) (p = 0.77), F7 (p = 0.76), frontal zone (Fz) (p = 0.65), F4 (p = 0.91), and F8 (p = 0.42).
No takes yet. Share an insight, caveat, or question.
Vinurajkumar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: